我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

瑞舒伐他汀对不同血脂、C反应蛋白水平的不稳定型心绞痛患者颈动脉粥样硬化斑块的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2014年第3期
页码:
289-292
栏目:
临床研究
出版日期:
2014-03-20

文章信息/Info

Title:
Effect of rosuvastatin calcium on carotid atherosclerotic plaques in unstable angina patients with different lipid and C-reactive protein levels
作者:
张 环1; 赵志敬2; 吴冠吉1
(1.西安市中心医院心内科，陕西 西安 710003；
2.第四军医大学西京医院心内科, 陕西 西安 710032)
Author(s):
ZHANG Huan1;  ZHAO Zhi jing2;  WU Guan ji1
(1.Department of Cardiology, Xi’an Central Hospital, Xi’an 710003, Shaanxi, China;
2.Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
瑞舒伐他汀; 低密度脂蛋白胆固醇; 超敏C反应蛋白; 粥样硬化斑块
Keywords:
rosuvastain;  low-density lipoprotein cholesterol;  high-sensitivity C-reactive protein;  atherosclerotic plaque
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的:探讨瑞舒伐他汀对不同血脂、C反应蛋白（CRP）水平的不稳定型心绞痛（UAP)患者颈动脉粥样硬化斑块的影响。方法:测定60例UAP患者低密度脂蛋白胆固醇（LDL-C）、超敏CRP（hsCRP）水平，并以LDL-C和hsCRP中位数水平为基础将受试者分为4组，所有入选患者口服瑞舒伐他汀10 mg/d，治疗12个月，分别于治疗前及治疗后3、6、9和12个月时测定三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）、LDL-C、hsCRP水平，以及颈动脉中层厚度（IMT），并计算颈动脉斑块积分。结果:经瑞舒伐他治疗9个月，高LDL-C，高hsCRP组颈动脉斑块积分较治疗前下降(P<0.05)，治疗12个月时下降更为显著(P<0.01)；并且，高LDL-C低hsCRP组颈动脉斑块积分下降程度不如低LDL-C高hsCRP组明显；而低LDL-C低hsCRP组颈动脉斑块积分与治疗前相比无统计学意义。结论:hsCRP的检测可以作为是否进行他汀类药物治疗的参考指标，尤其是对于那些LDL-C降至正常水平的患者。
Abstract:
AIM:To observe the influence of shuxuening on high-sensitivity Creactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) in patients with unstable angina pectoris (UAP). METHODS: One hundred UAP patients were randomly divided into two groups: control group and therapy group, with 50 cases in each group. For 14 days, the control group was treated with the conventional treatment and the therapy group was treated with a combination of shuxuening (30 ml) with glucose injection (250 ml) once a day in addition to the conventional treatment. The levels of hs-CRP and MMP-9 were detected immediately, 12 h, 24 h, 48 h, 7 days and 14 days after hospitalization. RESULTS: hs-CRP level increased gradually, reached its peak at 24 h after hospitalization, and then decreased. MMP-9 level increased in the first 12 h and then decreased. Compared with those in the control group, levels of hs-CRP and MMP-9 decreased significantly at 12 h, 24 h, 48 h, 7 days and 14 days after hospitalization in the therapy group. CONCLUSION: Shuxuening can maintain the stability of atheromatous plaques by decreasing the levels of hs-CRP and MMP9 in UAP patients.

参考文献/References

[1]Downs JR,Clearfield M,Weis S,et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS.Air Force/Texas Coronary AtherosclerosisPrevention Study[J].JAMA,1998,279(20):1615-1622.
[2]Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial[J].Lancet,2002,360(9326):7-22.
[3]Ridker PM,Rifai N,Pfeffer MA.Inflammation,pravastatin,and the risk of coronary events after myocardial infarction in patients with average cholesterol levels.Cholesterol and Recurrent Events(CARE)Investigators[J].Circulation,1998,98(9):839-844.
[4]Ridker PM,JUPITER Study Group.Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein:rationale and design of the JUPITER trial[J].Circulation Research,2003,108(19):2292-2297.
[5]Sukhova GK,Williams JK,Libby P,et al.Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol[J].Arterioscler Thromb Vasc Biol,2002,22(9):1452-1458.
[6]Yamasaki Y,Kodmna M,Nishizawa H,et al.Carotid intima-media thinckness in Japanese type 2 diabetic subjects:predietiors of progression and relationship with incident coronary heart disease[J].Diabetes Care,2000,23(9):1310-1315.
[7]Anderson AD,Uehata A,Gerhard MD,et al.Close relation of endothelial function in the human coronary and peripheral circulation[J].J Am Coll Cardiol,1995, 26(5):1235-1241.
[8]Ridker PM, Rifai N,Rose L,et al.Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J].N Engl J Med,2002,347(20):1557-1565.
[9]Seljeflot I,Tonstad S,Hjermann I.Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease[J].Atherosclerosis,2002,162(1):179-185.
[10]罗助荣,盖晓波.不稳定性心绞痛患者调脂干预对颈动脉粥样硬化及C反应蛋白的影响[J].中华心血管病杂志,2004,32(11):977-980.
[11]Devaraj S,Xu DY,Jialal I.C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells:implications for the metabolic syndrome and atherothrombosis[J].Circulation,2003,107(3):398 -404.
[12]Verma S,Devaraj S,Jialal I.Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis[J].Circulation,2006,113(17):2135-2150.
[13]Danenberg HD,Szalai AJ,Swaminathan RV,et al.Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice[J].Circulation,2003, 108(5):512-515.
[14]Ridker PM,Cannon CP,Morrow D,et al.C-reactive protein levels and outcomes after statin therapy[J].N Engl J Med,2005,352(1):20-28.
[15]Peters SA,Palmer MK,Grobbee DE,et al.C-reactive protein lowering with rosuvastatin in the METEOR study[J].J Intern Med,2010,268(2):155-161.
[16]Nohara R, Daida H, Hata M, et al. Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness［J］. Circ J, 2013, 77(6):1526-1533.
[17]Nohara R, Daida H, Hata M. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in japanese patients: Justification for Atherosclerosis Regression Treatment(JART)study[J].Circ J,2012,76(1):221-229.
[18]Jensen LO,Thayssen P,Pedersen KE,et al.Regression of coronary artheoselerosis by simvastain:a serial intravascular urtrasound study[J].Circulation,2004,110(3):265-270.

备注/Memo

备注/Memo:
收稿日期：2013-09-02.
作者简介：张环，副主任医师，硕士 Email：doczhanghuan@163.com
更新日期/Last Update: 2014-03-21